Who owns Lexeo Therapeutics, Inc., from the filings themselves: stakes over 5% (Schedule 13D/G), the institutional managers reporting the stock each quarter (13F), and the funds holding it (N-PORT).
Investors crossing 5% ownership must disclose it. Schedule 13G filers certify the stake is passive; Schedule 13D is the general form for everyone else — founders, strategic holders, and activists alike. Each entry is the holder's most recent disclosure. Coverage begins with SEC's structured filings from December 18, 2024; a holder appears once they file or amend after that date.
OrbiMed Advisors LLC: 4.1% · 3,203,050 shares — OrbiMed Capital LLC: 1.0% · 744,800 shares
BALYASNY ASSET MANAGEMENT L.P.: 10.0% · 7,844,311 shares — BAM GP LLC: 10.0% · 7,844,311 shares — Balyasny Asset Management Holdings LP: 10.0% · 7,844,311 shares
18 more 5% stakes behind a free account
See every investor who has disclosed crossing 5% of Lexeo Therapeutics, Inc..
Sign up freeEvery institutional manager whose latest 13F reports this stock, largest position first. "% of their portfolio" is the weight inside that manager's own book — how much conviction the position represents; "% of company" is how much of Lexeo Therapeutics, Inc. they hold. Together these 189 managers report 125.72% of shares outstanding.
| Investor | Position value | Shares | % of their portfolio | % of company | As of |
|---|---|---|---|---|---|
| VANGUARD GROUP INC | $38.7M | 3,894,310 | 0.00% | 4.75% | December 31, 2025 |
| MONTANOVA CAPITAL, LLC | $29.7M | 6,384,200 | 0.54% | 7.78% | June 30, 2026 |
187 more institutional holders behind a free account
See every manager reporting Lexeo Therapeutics, Inc., how much of the company they hold, and how big the position is inside their own portfolio.
Sign up freeFunds disclosing this stock in their monthly N-PORT portfolio, with the position's share of the fund's net assets. Together these 141 funds hold 18.96% of shares outstanding — counted inside the manager totals above, not on top of them, since a fund's shares also appear in its manager's 13F.
| Fund | Position value | % of net assets | % of company | As of |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | $11.3M | 0.11% | 2.96% | June 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | $10.9M | 0.00% | 2.85% | June 30, 2026 |
139 more funds behind a free account
See every fund holding Lexeo Therapeutics, Inc. and what share of its net assets the position represents.
Sign up freeLoading...
